ALX Oncology (ALXO) announced receipt of U.S. Food and Drug Administration clearance for the Investigational New Drug application for ALX2004, the company’s antibody-drug conjugate for the treatment of epidermal growth factor receptor-expressing solid tumors. Based on this clearance, ALX Oncology will initiate a single-agent dose-escalation and expansion Phase 1 clinical trial for ALX2004 in mid-2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- ALX Oncology Holdings: Balancing Growth Potential and Uncertainty with a Hold Rating
- ALX Oncology price target lowered to $1.50 from $3 at Stifel
- Promising Developments in ALX Oncology’s Clinical Pipeline Justify Buy Rating
- ALX Oncology Reports 2024 Financial Results and Updates
- ALX Oncology files $364.12M mixed securities shelf